Company: ENTXW
Filing Date: 2025-06-06
Form Type: 424B3
Source: 0001178913-25-002133
Chunk: 5

Company: Entera Bio Ltd.
Filing Date: 2025-06-06
Form: 424B3
Chunk 5
---
 1A. Risk Factors” in our 2024 Annual Report and in any updates to those risk factors in our Quarterly Reports on Form 10-Q or subsequent Annual Reports on Form 10-Ks and Quarterly Reports on Form 10-Q incorporated by reference herein, as well as the other information in this prospectus before making an investment in our ordinary shares. Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our ordinary shares could decline and you could lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements.” Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors. Risks related to this offering and ownership of our ordinary shares The price of our ordinary shares may be volatile, and holders of our ordinary shares could lose all or part of their investment. The price of securities for publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile in the future. The market price of our ordinary shares on Nasdaq may fluctuate as a result of a number of factors, some of which are beyond our control, including, but not limited to:

| • | clinical trial results and the timing of the release of such results; |

| • | the amount of our cash resources and our ability to obtain additional funding; |

| • | announcements of research activities, business developments, technological innovations or new products, or acquisitions or expansion plans by us or our competitors; |

| • | success or failure of our research and development projects or those of our competitors; |

| • | our entering into or terminating strategic relationships; |

| • | changes in laws or government regulation; |

| • | actual or anticipated fluctuations in our and our competitors’ results of operations and financial condition; |

| • | regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products; |

| • | departure of our key personnel; |

| • | disputes related to proprietary rights, including patents, litigation matters and our ability to obtain intellectual property protection for our technologies; |

| • | our sale, or the sale by our significant shareholders, of ordinary shares or other securities in the future; |

| • | public concern regarding the safety, efficacy or other aspects of the products or methodologies we are developing;